Mumbai: Ranbaxy Laboratories Ltd shares were down over 1 per cent in early trade on Tuesday after the generic drugmaker pleaded guilty to US felony charges related to drug safety and will pay $500 million in civil and criminal fines.
The settlement is its largest-ever with a generic drugmaker over drug safety, according to the US government.
Ranbaxy USA pleaded guilty to three felony counts related to the manufacture of drugs at two Indian locations that did not meet safety standards and to four counts of making material false statements.
...
more
10:13 AM, May 14, 2013
New Delhi: Generic drugmaker Ranbaxy has been fined $500 million by the US government after its subsidiary pleaded guilty to sale of adulterated drugs manufactured in India. It is the largest settlement by a generic medicine maker till date. It includes $150 million in payments for a criminal fine and forfeiture and $350 million in payments for civil claims. The adulterated drugs were made in Ranbaxy's plants in India and...
08:30 AM, May 14, 2013
Prathiba M Singh, advocate for Ranbaxy and Cipla, fought the Glivec patent case against Novartis. She joined IBNLive readers for an interaction on the legal and moral compulsions behind this courtroom battle and the significance of the Supreme Court's decision for Indian pharma firms and the people of the country. ...
06:33 PM, Apr 03, 2013
The US arm of Indian drug major Ranbaxy Laboratories has entered into an in-licensing agreement with Alembic Pharmaceuticals Limited to exclusively market the generic version of Pfizer Inc.'s anti-depression drug Pristiq in the US. ...
01:55 PM, Mar 06, 2013
New Delhi: Ranbaxy Laboratories on Friday said it has launched generic pioglitazone hydrochloride tablets used for treating diabetes in the American market under an agreement with Takeda Pharmaceuticals USA Inc. The company's wholly-owned subsidiary Ranbaxy Pharmaceuticals Inc has launched the drug following the expiry of patent held by Takeda Pharmaceutical. Ranbaxy is among the three companies, including Teva and Mylan, to have 180-days of marketing exclusivity for the drug in...
05:34 PM, Aug 17, 2012
Kamal K Sharma Designation: Managing Director, Lupin The Challenge: To enter the Japanese market, the world's second largest pharmaceutical market How He Did It: By entering the market with a partner and using them to understand the nuances. Lupin eventually bought the partner out, but made sure no changes were made to its management or operations In Japan, you just can't walk in and do business. It is a market...
04:46 PM, May 11, 2012
Mumbai: Share prices of Ranbaxy tumbled nearly 7 per cent in the morning trade on Friday after a consent decree was filed in a United States court that requires the drug firm to make fundamental changes at its plants in the US and India. The US Justice Department filed a "ground-breaking" consent decree in court on Thursday, mandating Indian drug-maker Ranbaxy to adhere to US manufacturing standards and ensure integrity...
12:01 PM, Jan 27, 2012
Washington: Indian pharma major Ranbaxy faces the possibility of a permanent injunction, which requires it to make fundamental changes to its plants both in the US and India and would prevent it from manufacturing drugs at certain facilities in the US. This follows the US Justice Department's unprecedented action in filing a ground-breaking consent decree in a court in Maryland at the request of the Food and Drug Administration. "This...
06:00 PM, Jan 26, 2012
Cipla, Ranbaxy, Hetero, Roche and Natco Pharma are in the race. ...
12:37 AM, Aug 13, 2009
Atul Sobti says that Ranbaxy will remain a listed company. ...
01:47 PM, May 25, 2009
Indian pharma giant has customers in 125 countries and alliances in 49 countries. ...
06:08 PM, May 24, 2009
Company says it will respond to American regulator's letter. ...
11:32 AM, Feb 26, 2009
Ranbaxy CEO will also assume the role of an Executive Chairman. ...
02:55 AM, Dec 20, 2008
The motion claimed that Ranbaxy had failed to comply FDA standards. ...
05:49 PM, Oct 08, 2008
Rudy Guiliani will help Ranbaxy resolve a US Food and Drug ban. ...
04:21 PM, Sep 18, 2008
Ranbaxy-Daiichi Sankyo is still good despite the co's trouble with US laws. ...
03:47 AM, Sep 18, 2008
US FDA banned more than 30 generic drugs produced by Ranbaxy. ...
10:44 AM, Sep 17, 2008
Sensex fell 45 points to 13473 and the Nifty lost 11 points at 4,064. ...
10:44 AM, Sep 17, 2008
The Indian drug giant, Ranbaxy is a major maker of an AIDS generic drug. ...
01:45 AM, Sep 17, 2008
Daiichi Sankyo to pump in Rs 10,000 crores to acquire stake in Ranbaxy. ...
05:49 PM, Aug 05, 2008
